It is the most common thing to go slightly wrong after breast surgery, and one of the least explained to patients. A seroma is a collection of clear straw-coloured fluid in the space left behind after mastectomy or around an implanted device. Most are harmless and settle; a minority become the first domino in a chain that ends in infection or implant loss. This article explains why seromas form, what raises the risk, how they are managed, and why they matter more in reconstruction than in mastectomy alone.
Why seromas form
Mastectomy creates a large raw surface and divides lymphatic channels that previously drained the breast. In the days that follow, inflammatory exudate and lymph collect in the dead space between the chest wall and the skin flaps. Add an implanted device or a soft-tissue matrix, and there is a second interface that must revascularise and integrate before the space closes biologically. Until it does, fluid has somewhere to go.
What raises the risk
- Extent of surgery. Axillary lymph node dissection is the strongest single driver, considerably more than sentinel node biopsy alone.
- Dead space and flap mobility. Large breasts, extensive undermining and poor apposition between flap and chest wall all leave more space for fluid.
- Patient factors. High BMI is consistently associated with higher seroma rates across published series.
- Device and matrix factors. Matrix-assisted reconstruction reports higher seroma rates in several cohorts, discussed with sources in our article on matrix complications. Rates vary widely by protocol, matrix preparation and how a seroma is defined, which is why cross-study comparison is unreliable.
Why it matters more in reconstruction
After a mastectomy alone, a seroma is usually an inconvenience: aspirated once or twice, resolved. Around an implant, the same fluid is a culture medium sitting against a foreign body that cannot be washed by the immune system the way vascularised tissue can. Several series link persistent seroma to subsequent infection, and infection to explantation. It also delays matrix integration, prolonging exactly the avascular window the reconstruction is trying to shorten. This is why units treat persistent post-reconstruction seroma actively rather than expectantly.
Prevention
The measures that recur across the literature are unglamorous and effective: closed suction drainage with unit-specific removal criteria, meticulous haemostasis, obliterating dead space with quilting or flap fixation sutures where appropriate, complete apposition of any matrix to the flap without gaps, and attention to matrix preparation per its instructions for use. Drain protocols differ genuinely between units, and evidence supports a range of practices rather than one right answer.
Management
Small, asymptomatic seromas are observed; the body reabsorbs most of them. Symptomatic or persistent collections are aspirated under sterile conditions, often more than once, with ultrasound guidance where the collection is loculated or the anatomy uncertain. Seroma that recurs repeatedly, or that appears alongside erythema, tenderness, fever or raised inflammatory markers, is treated as potential infection until proven otherwise, and management escalates to imaging, culture, antibiotics and in some cases surgical washout or device removal. Late seromas appearing months or years after reconstruction always warrant investigation rather than simple aspiration.
What patients should expect
Some fluid is normal; drains exist precisely because of it. Patients should know how long drains typically stay, what output threshold their unit uses to remove them, that aspiration in clinic is a routine procedure rather than a sign of failure, and which symptoms mean calling the team rather than waiting for the next appointment: spreading redness, increasing pain, fever, or fluid that returns rapidly after aspiration. Our recovery timeline sets this in the wider context of healing.
The bottom line
Seroma is the predictable consequence of the space mastectomy leaves behind, common, usually benign, and genuinely consequential when a device is involved. Prevention is about dead space and drainage; management is about distinguishing sterile fluid from early infection quickly. Neither is exotic, and both determine how many reconstructions reach their intended result.
Key published sources
- Smith JM, et al. Complications associated with acellular dermal matrix use in implant-based breast reconstruction. Gland Surgery. 2023.
- Weichman KE, et al. Sterile ready-to-use ADM, infection and seroma outcomes in reconstruction. Plastic and Reconstructive Surgery. 2015.
- Systematic reviews of drainage and quilting techniques for seroma prevention after mastectomy, breast surgical literature.
Important information This article is general education, not medical advice. Tap to read the full medical, regulatory & legal notice.
This article is provided by Advanced Biomedical Concept for general informational and educational purposes only. It does not constitute medical, surgical, diagnostic, or other professional healthcare advice, and it is not a substitute for consultation with a suitably qualified healthcare professional. Reading it creates no doctor–patient or other professional relationship. Nothing here should be used to diagnose, treat, cure, or prevent any disease or condition, or to make decisions about medical care. Always seek the advice of a physician or other qualified provider with any questions about a medical condition or treatment, and never disregard or delay professional advice because of something you have read here.
Any reference to Advanced Biomedical Concept products (including ExaShape and ExaFat) is provided for general information only. These are medical devices intended to be used by appropriately trained healthcare professionals strictly in accordance with their applicable, current Instructions for Use (IFU). Regulatory status (including CE marking and classification under the EU Medical Device Regulation), market availability, and approved indications differ between countries and may change over time; a device referred to here may not be available or approved in your country. This content is not intended as, and must not be relied upon as, a statement or claim of safety, clinical performance, or efficacy beyond what is set out in the applicable IFU and current regulatory approvals. Product-specific information is directed at healthcare professionals and is not intended to promote, advertise, or offer any medical device to the general public where such promotion is restricted or prohibited by law.
Statements reflect information believed to be accurate at the date of publication and may be updated or corrected without notice. Any statements regarding the future are expectations or general views, not guarantees. Clinical outcomes depend on many individual factors, results vary from person to person, and no particular result is promised or implied. Where third-party studies, sources, or external links are referenced, they are provided for convenience and information only and do not imply endorsement, and Advanced Biomedical Concept is not responsible for their content.
To the fullest extent permitted by applicable law, Advanced Biomedical Concept and its officers, employees, contributors, and representatives (each acting in that capacity and on behalf of Advanced Biomedical Concept) accept no liability for any loss, injury, or damage of any kind arising directly or indirectly from use of, or reliance on, this content. Nothing in this notice excludes or limits any liability that cannot lawfully be excluded or limited.
Questions about this material can be directed to us via our contact page.
Last reviewed: August 24, 2026.